Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZAI LAB LIMITED

(ZLAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zai Lab Limited Announces Positive Results from a Randomized and Efficacy of a Topical Formulation of Zl-1102 in Adults with Mild-To-Moderate Chronic Plaque Psoriasis

10/20/2021 | 04:05pm EST

Zai Lab Limited announced positive topline results from a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept and first-in-human study to evaluate the safety, pharmacokinetics, and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP). ZL-1102 is an investigational, novel human VH antibody fragment, targeting the IL-17A cytokine and is formulated for topical use. In efficacy data in 51 evaluable patients; Treatment with ZL-1102 showed approximately a 45% relative improvement compared to placebo in the local Psoriasis Area Severity Index (PASI)1 score of the target lesion at four weeks. A trend of increasing efficacy compared to placebo was observed over time, and clinical benefit was maintained after the end of treatment up to six weeks, Anti-inflammatory effects were observed, with clear improvement in erythema of the target lesion up to four weeks, maintained after the end of treatment up to six weeks. Clinical improvement in scaling was also observed, ZL-1102 showed consistent clinical improvement in target lesion size (reduction in area) compared to an area increase in the placebo arm during the treatment period and ZL-1102 showed consistently higher responder rates over time compared to placebo up to four weeks and maintained after the end of treatment up to six weeks. The responder rate in this study was defined as the percentage of patients who achieved a =50% reduction compared to baseline in local PASI score of the target lesion, measured weekly. Safety data in 53 evaluable patients showed; A benign safety and tolerability profile comparable to placebo, with treatment-emergent adverse events that were few in number and mild and Pharmacokinetic studies confirmed lack of systemic absorption of the compound.


ę S&P Capital IQ 2021
All news about ZAI LAB LIMITED
12/07Asian ADRs Climb Higher in Tuesday Trading
MT
12/05Zai Lab's Ovarian Cancer Treatment Added to China's National Reimbursement Drug List; S..
MT
12/03Citigroup Raises Price Target for Zai Lab to $231 From $217, Maintains Buy Rating
MT
12/03Zai Lab Says New Indication for Its Ovarian Cancer Drug Added to China's National Reimb..
MT
12/03Zai Lab Announces Inclusion of Zejula? in China's National Reimbursement Drug List for ..
CI
12/03ZAI LAB : Announces Inclusion of ZEJULA« (Niraparib) in China's National Reimbursement Dru..
PU
12/03ZAI LAB LTD : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
12/03Zai Lab Announces Inclusion of ZEJULA« (Niraparib) in China's National Reimbursement Dr..
AQ
11/30Zai Lab's Late-Stage Ovarian Cancer Trial Meets Primary Endpoint
MT
11/30Zai Lab Study for Ovarian Cancer Treatment Meets Primary Endpoint
DJ
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2021 152 M - -
Net income 2021 -609 M - -
Net cash 2021 1 397 M - -
P/E ratio 2021 -10,7x
Yield 2021 -
Capitalization 6 847 M 6 847 M -
EV / Sales 2021 35,9x
EV / Sales 2022 19,0x
Nbr of Employees 1 194
Free-Float 99,9%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 71,02 $
Average target price 196,69 $
Spread / Average Target 177%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Tao Fu President, Chief Operating Officer & Director
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-47.52%6 847
CSL LIMITED7.48%99 422
WUXI BIOLOGICS (CAYMAN) INC.-0.97%55 500
SAMSUNG BIOLOGICS CO.,LTD.10.65%51 558
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-4.14%34 479